Eisai Submits LEQEMBI Autoinjector Application, FDA Grants Priority Review
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3d ago
0mins
Source: NASDAQ.COM
- FDA Review Progress: Eisai's Supplemental Biologics License Application (sBLA) has been accepted for review by the FDA, with a decision expected by May 24, 2026, potentially providing new treatment options for Alzheimer's patients.
- At-Home Injection Innovation: If approved, LEQEMBI IQLIK will be the first anti-amyloid treatment to offer at-home injection options, aimed at improving medication convenience and adherence for patients with early Alzheimer's disease.
- Global Market Presence: LEQEMBI is currently approved in 53 countries and regions and is under regulatory review in 7 countries, demonstrating Eisai's strong influence and expansion potential in the global market.
- Collaborative Promotion Model: Eisai and Biogen co-commercialize LEQEMBI, with Eisai leading global development and regulatory submissions, ensuring effective market promotion and decision-making authority.
Analyst Views on BIIB
Wall Street analysts forecast BIIB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIIB is 186.19 USD with a low forecast of 135.00 USD and a high forecast of 250.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
25 Analyst Rating
11 Buy
13 Hold
1 Sell
Moderate Buy
Current: 174.120
Low
135.00
Averages
186.19
High
250.00
Current: 174.120
Low
135.00
Averages
186.19
High
250.00
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
